EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer

Shin-Chih Lin, Ya-Chuan Tsai, Ying-Lan Chen, Hui-Kuan Lin, Yun-Chen Huang, Yi-Syuan Lin, Yu-Sheng Cheng, Hsing-Yi Chen, Chia-Jung Li, Tsung-Yen Lin, Shih-Chieh Lin

Drug Resistance Updates · 2024-11 · 77 · 101144

DOI: 10.1016/j.drup.2024.101144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-11. Verfasst von Shin-Chih Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Nitriles, Drug Resistance, Neoplasm, Benzamides. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health Research Institutes, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: The recent approval of enzalutamide for metastatic castration-sensitive prostate cancer underscores its growing clinical significance, raising concerns about emerging resistance and limited treatment options. While the reactivation of the androgen receptor (AR) and other genes plays a role in enzalutamide resistance, identifications of novel underlying mechanism with therapeutic potential in enzalutamide-resistant (EnzaR) cells remain largely elusive. METHODS: Drug-resistant prostate cancer cell lines, animal models, and organoids were utilized to examine NUDT21 function by transcriptomic and metabolomic analyses through loss-of-function and gain-of-function assays. Notably, a mono-methylation monoclonal antibody and conditional-knockin transgenic mouse model of NUDT21 were generated for evaluating its function. RESULTS: NUDT21 overexpression acts as a crucial alternative polyadenylation (APA) mediator, supported by its oncogenic role in prostate cancer. PRMT7-mediated mono-methylation of NUDT21 induces a shift in 3'UTR usage, reducing oncogenicity. In contrast, its un-methylation promotes cancer growth and cuproptosis insensitivity in EnzaR cells by exporting toxic copper and suppressing docosahexaenoic acid (DHA) biosynthesis. Crucially, NUDT21 inhibition or DHA supplementation with copper ionophore holds therapeutic promise for EnzaR cells. CONCLUSIONS: The un-methylation of NUDT21-mediated 3'UTR shortening unveils a novel mechanism for enzalutamide resistance, and our findings offer innovative strategies for advancing the treatment of prostate cancer patients experiencing enzalutamide resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylthiohydantoinNitrilesDrug Resistance, NeoplasmBenzamidesDocosahexaenoic AcidsMaleAnimalsHumansMiceCell Line, TumorMethylationMice, TransgenicProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsGene Expression Regulation, NeoplasticAntineoplastic Agents

Stichwörter der Autor:innen

3’UTR usage switchCuproptosis insensitivity and DHAEnzalutamide resistanceMono-methylationNUDT21

Substanzen

PhenylthiohydantoinenzalutamideNitrilesBenzamidesDocosahexaenoic AcidsAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan.
  • Department of Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, 701, Taiwan; University Center of Bioscience and Biotechnology, National Cheng Kung…
  • Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA; Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
  • Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan.
  • Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan.
  • Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung, 813, Taiwan.

Förderung

  • National Health Research Institutes
  • National Science and Technology Council

Zitieren

APA

Lin, S. C., Tsai, Y. C., Chen, Y. L., Lin, H. K., Huang, Y. C., Lin, Y. S., Cheng, Y. S., Chen, H. Y., Li, C. J., Lin, T. Y., & Lin, S. C. (2024). Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer. Drug Resistance Updates, 77, 101144. https://doi.org/10.1016/j.drup.2024.101144

Vancouver

Lin SC, Tsai YC, Chen YL, Lin HK, Huang YC, Lin YS, et al. Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer. Drug Resistance Updates. 2024;77:101144. doi:10.1016/j.drup.2024.101144

BibTeX
@article{Lin2024,
  author = {Lin, Shin-Chih and Tsai, Ya-Chuan and Chen, Ying-Lan and Lin, Hui-Kuan and Huang, Yun-Chen and Lin, Yi-Syuan and Cheng, Yu-Sheng and Chen, Hsing-Yi and Li, Chia-Jung and Lin, Tsung-Yen and Lin, Shih-Chieh},
  title = {Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer},
  journal = {Drug Resistance Updates},
  year = {2024},
  volume = {77},
  pages = {101144},
  doi = {10.1016/j.drup.2024.101144}
}
Kostenlos starten →